Back to search results

MRI of the Pancreas for Cancer Screening

This study is looking at a special type of MRI scan for the pancreas (MRP) to see if it can better find pancreatic cancer in people who are at high risk. Researchers will compare the quality of images from this new MRP scan to a standard MRI scan (conventional MRCP). You might be able to join if you are 18 or older and have a strong family history of pancreatic cancer, or if you have certain genetic changes (like in ATM, BRCA1, BRCA2, CDKN2A, PALB2, STK11, or TP53) that increase your risk. The study aims to enroll 79 participants and is currently unclear about its recruitment status.

Study design
This is an observational study, meaning participants will be observed without receiving an experimental treatment. It plans to enroll 79 participants.
What's involved
Participants will have a single MRI of the abdomen without contrast. An endoscopic ultrasound (EUS) will be scheduled on the same day or within two weeks before the MRP.
Compensation
Not stated in the trial record.
Follow-up
The study will compare image quality for up to 3 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07612046

A Study of Magnetic Resonance Imaging of the Pancreas for Cancer Screening

Recruiting
Not specifiedAges 18+Observational
Memorial Sloan Kettering Cancer Center
~79 participants
Updated 2026-07-09 on ClinicalTrials.gov
What's tested:MRIEndoscopic ultrasound

At a glance

Recruiting sites
7 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Compare image quality of novel high-resolution magnetic resonance pancreas (MRP) to conventional MRCP
Measured over Up to 3 years

Conditions

Pancreatic Cancer
Pancreas Cancer

Explore related trials

Pancreatic CarcinomaAPC GeneATM GeneBRCA1 GeneBRCA2 GeneCDKN2A GeneCPA1 GeneCTRC GeneDNA Mismatch Repair Protein Mlh1EPCAM GeneMSH2 GeneMSH6 GenePancreatic Secretory Trypsin InhibitorPartner and Localizer of BRCA2PMS2 GeneSTK11 GeneTP53 GeneTrypsin-1

Where it's being run

7 sites across 2 states
New York4
New Jersey3

Study leadership

  • Richard Kinh Gian Do, MD, PhD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Richard Kinh Gian Do, MD, PhD
[email protected]
212-639-8591
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Two first-degree relatives with pancreas cancer, one being a first-degree relative to the individual
Pathogenic mutation in APC, BRCA1, MLH1, MSH2, MSH6, PMS2, EPCAM, PALB2, or TP53 and a first/second-degree relative with pancreas cancer
Pathogenic mutation in CDKN2A/p16, STK11, PRSS1, SPINK1/PST1, CTRC, CPA1, ATM, or BRCA2
Meets surveillance age eligibility, which is typically age 50, or 10 years earlier than the youngest relative with pancreas cancer. For individuals with certain gene mutations, this can be earlier. All participants must be aged 21+
Consents to follow-up contact
US residents
Completed MRI with MRCP with no actionable findings related to the pancreas (e.g. a pancreatic mass)
No metallic artifacts covering the pancreas on prior MRCP
Scheduled for endoscopic ultrasound
No new contraindications for MRI (e.g. new MR unsafe device)
No history of claustrophobia or use of anxiolytic on prior MRI
No history of abdominal surgery that may affect interpretation of either EUS or MR
No medical conditions that confers increased and/or unacceptable risk for anesthesia
Documentation of Disease
Definition of Disease N/A
Required Organ Function N/A

What this trial measures

  • Compare image quality of novel high-resolution magnetic resonance pancreas (MRP) to conventional MRCPUp to 3 years

    Develop and pilot a focused high-resolution magnetic resonance pancreas (MRP) exam to help facilitate early pancreatic cancer detection in high-risk individuals. Image quality for T1, T2, and DWI sequences performed on the novel MRP exam will be compared to conventional MRCP performed in the same participants.